破解同源重组缺陷密码:如何识别PARP抑制剂应答者
本文综述现有同源重组缺陷(HRD)检测方法,将其分为检测HRD病因、研究HRD后果和评估HR活性本身三大类,旨在探讨如何通过HRD检测识别可能从PARP抑制剂(PARPi)治疗中获益的患者。
要点
- DNA双链断裂是最关键的DNA损伤,其修复受严密调控以维持细胞完整性。
- 部分肿瘤存在同源重组缺陷(HRD),对PARP抑制剂(PARPi)更敏感。
- PARPi已在BRCA突变卵巢癌中显示显著疗效,适应症逐步扩展至乳腺、前列腺和胰腺等肿瘤部位。
核心结论
- 当前主要挑战是开发能够检测肿瘤HRD表型(HRD检测)并预测PARPi敏感性的检测方法,以选择可能从该治疗中获益的患者。
研究设计与样本
- 本文为综述,对现有HRD检测方法进行综合,将其分为检测HRD病因、研究HRD后果和评估HR活性本身三大类。
主要发现
- PARPi已在BRCA突变卵巢癌中显示显著疗效多年,其适应症已逐步扩展至乳腺、前列腺和胰腺等其他肿瘤部位。
- 近期PARPi被证明在BRCA突变之外具有HRD表型的癌症中有效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DNA double-strand breaks are the most critical DNA damage to cells, and their repair is tightly regulated to maintain cellular integrity. Some cancers exhibit homologous recombination deficiency (HRD), a faithful double-strand break repair system, making them more sensitive to poly (ADP ribose) polymerase inhibitors (PARPi). PARPi have shown substantial efficacy in BRCA-mutated ovarian cancer for several years, and their indication has gradually been extended to other tumour locations such as breast, prostate and pancreas. More recently, PARPi were demonstrated to be effective in cancers with an HRD phenotype beyond BRCA mutations. Today, a major challenge is developing tests capable of detecting the HRD phenotype of cancers (HRD tests) and predicting sensitivity to PARPi to select patients likely to benefit from this therapy. This review provides a synthesis of the existing HRD tests, divided into three main approaches to detect HRD: the investigation of the HRD causes, the study of its consequences and the evaluation of the HR activity itself.
引用
- Paulet L, Trecourt A, Leary A, et al. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. Eur J Cancer. 2022. PMID: 35279473. doi:10.1016/j.ejca.2022.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。